Abstract
Human granulocyte colony-stimulating factor (G-CSF, this study used Fc-fused recombinant G-CSF; GX-G3) is an important glycoprotein that stimulates the proliferation of granulocytes and white blood cells. Thus, G-CSF treatment has been considered as a crucial regimen to accelerate recovery from chemotherapy-induced neutropenia in cancer patients suffering from non-myeloid malignancy or acute myeloid leukemia. Despite the therapeutic advantages of G-CSF treatment, an assessment of its immunogenicity must be performed to determine whether the production of anti-G-CSF antibodies causes immune-related disorders. We optimized and validated analytical tools by adopting validation parameters for immunogenicity assessment. Using these validated tools, we analyzed serum samples from rats and monkeys injected subcutaneously with GX-G3 (1, 3 or 10 mg/kg once a week for 4 weeks followed by a 4-week recovery period) to determine immunogenicity response and toxicokinetic parameters with serum concentration of GX-G3. Several rats and monkeys were determined to be positive for anti-GX-G3 antibodies. Moreover, the immunogenicity response of GX-G3 was lower in monkeys than in rats, which was relevant to show less inhibition of toxicokinetic prof...Continue Reading
References
Jul 18, 1991·The New England Journal of Medicine·J CrawfordG Rausch
Jan 1, 1989·Immunologic Research·H E Broxmeyer, S Vadhan-Raj
Apr 1, 1987·The Journal of Experimental Medicine·K WelteL M Souza
Apr 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A M CohenL M Souza
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V Trillet-LenoirD Tomita
Jan 21, 2000·Experimental Hematology·G MolineuxG Schwab
Jan 4, 2001·Journal of the National Cancer Institute·R García-CarboneroL Paz-Ares
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Dec 28, 2002·Clinical Therapeutics·Huub Schellekens
Sep 26, 2003·Seminars in Oncology·Jeffrey Crawford
Jul 15, 2004·Journal of Immunological Methods·Anthony R Mire-SluisLinda A Zuckerman
Apr 9, 2008·Microbial Cell Factories·Ana Ls VanzDiógenes S Santos
Sep 30, 2008·Journal of the Neurological Sciences·Bruce A CohenGavin Giovannoni
Nov 11, 2008·Journal of Pharmaceutical and Biomedical Analysis·Gopi ShankarEugen Koren
Apr 7, 2009·Regulatory Toxicology and Pharmacology : RTP·Rafael PonceDan Wierda
Aug 27, 2010·Journal of Pharmaceutical Sciences·Satish Kumar Singh
Nov 12, 2010·Annals of the Rheumatic Diseases·Anna JamnitskiGerrit Jan Wolbink
Jul 2, 2011·Haematologica·Bronwen E ShawMichael A Pulsipher
Oct 1, 2011·PloS One·Se Jin ImYoung Chul Sung
Jul 28, 2012·EMBO Molecular Medicine·Daniel M CzajkowskyRichard J Pleass
Sep 27, 2012·Protein Expression and Purification·Jung-Hwan LeeChang-Shin Park
Aug 8, 2013·Journal of Immunotoxicology·Kirsty D RatanjiIan Kimber
Aug 9, 2013·MAbs·Peter J K van MeerHuub Schellekens
Mar 19, 2014·PloS One·George N CoxDaniel H Doherty